Ray Dalio’s ELV Holdings & Trades

First Buy
Q4 2014
Duration Held
44 Quarters
Largest Add
Q4 2024
+91,849 shares
Current Position
55,203 shares
$17.84 M value

Ray Dalio's ELV Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 55.2K shares of Elevance Health, Inc. (ELV) worth $17.84 M, representing 0.07% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 44 quarters.

Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in ELV, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2024, adding 91.8K shares. Largest reduction occurred in Q1 2020, reducing 122.2K shares.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Elevance Health (ELV) Holding Value Over Time

Track share changes against reported price movement

Quarterly Elevance Health (ELV) Trades by Ray Dalio

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2014 +27,141 New Buy 27,141 $125.68
Q1 2015 -7,600 Reduce 28.00% 19,541 $154.39
Q2 2015 +14,000 Add 71.64% 33,541 $164.13
Q3 2015 +2,600 Add 7.75% 36,141 $140.01
Q4 2015 -36,141 Sold Out 36,141 $0.00
Q1 2016 +18,900 New Buy 18,900 $138.99
Q2 2016 +24,100 Add 127.51% 43,000 $131.35
Q3 2016 +31,679 Add 73.67% 74,679 $125.31
Q4 2016 -75 Reduce 0.10% 74,604 $143.77
Q1 2017 -74,604 Sold Out 74,604 $0.00
Q3 2017 +6,199 New Buy 6,199 $189.87
Q4 2017 -6,199 Sold Out 6,199 $0.00
Q1 2018 +7,493 New Buy 7,493 $219.67
Q2 2018 -7,493 Sold Out 7,493 $0.00
Q1 2019 +21,217 New Buy 21,217 $286.99
Q2 2019 +23,117 Add 108.96% 44,334 $282.20
Q3 2019 +85,011 Add 191.75% 129,345 $240.10
Q4 2019 -129,345 Sold Out 129,345 $0.00
Q1 2020 +7,167 New Buy 7,167 $227.01
Q2 2020 -2,268 Reduce 31.65% 4,899 $262.91
Q3 2020 -4,899 Sold Out 4,899 $0.00
Q3 2021 +2,183 New Buy 2,183 $372.88
Q4 2021 +16,779 Add 768.62% 18,962 $463.56
Q1 2022 +16,505 Add 87.04% 35,467 $491.22
Q2 2022 +42,365 Add 119.45% 77,832 $482.58
Q3 2022 -30,110 Reduce 38.69% 47,722 $454.23
Q4 2022 +37,582 Add 78.75% 85,304 $512.97
Q1 2023 -50,917 Reduce 59.69% 34,387 $459.81
Q2 2023 +32,908 Add 95.70% 67,295 $444.29
Q3 2023 +28,008 Add 41.62% 95,303 $435.42
Q4 2023 +32,942 Add 34.57% 128,245 $471.56
Q1 2024 -64,905 Reduce 50.61% 63,340 $518.54
Q2 2024 -21,754 Reduce 34.34% 41,586 $541.86
Q3 2024 +20,463 Add 49.21% 62,049 $520.00
Q4 2024 +91,849 Add 148.03% 153,898 $368.90
Q1 2025 -70,557 Reduce 45.85% 83,341 $434.96
Q2 2025 -24,504 Reduce 29.40% 58,837 $388.96
Q3 2025 -3,634 Reduce 6.18% 55,203 $323.12

Ray Dalio's Elevance Health Investment FAQs

Ray Dalio first purchased Elevance Health, Inc. (ELV) in Q4 2014, acquiring 27,141 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Elevance Health, Inc. (ELV) for 44 quarters since Q4 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio's largest addition to Elevance Health, Inc. (ELV) was in Q4 2024, adding 153,898 shares worth $56.77 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 55,203 shares of Elevance Health, Inc. (ELV), valued at approximately $17.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Elevance Health, Inc. (ELV) represents approximately 0.07% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio's peak holding in Elevance Health, Inc. (ELV) was 153,898 shares, as reported at the end of Q4 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.